Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda(®)) to submit evidence of its clinical and cost effectiveness for the treatment of patients with r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoeconomics
Autors principals: Grimm, Sabine E., Fayter, Debra, Ramaekers, Bram L. T., Petersohn, Svenja, Riemsma, Rob, Armstrong, Nigel, Pouwels, Xavier, Witlox, Willem, Noake, Caro, Worthy, Gillian, Kleijnen, Jos, Joore, Manuela A.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2019
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6713293/
https://ncbi.nlm.nih.gov/pubmed/30895564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-019-00792-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars